TP53 and Miyoshi myopathy: Considering that TP53 alterations increase during progression of MM and are associated with drug resistance, it might be necessary to interact with TP53 pathway to be able to significantly improve outcomes of MM patients, or at least develop treatment strategies that do not select TP53 subclones (Jovanović et al. 2019).